Lv1
60 积分 2023-01-28 加入
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
1个月前
已完结
BRD4 Protein as a Target for Lung Cancer and Hematological Cancer Therapy: A Review
1个月前
已完结
Linker and Conjugation Site Synergy in Antibody–Drug Conjugates: Impacts on Biological Activity
1个月前
已完结
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
2个月前
已完结
Template-assisted covalent modification underlies activity of covalent molecular glues
2个月前
已完结
E3 ligase ligand chemistries: from building blocks to protein degraders
2个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3个月前
已完结
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
3个月前
已完结
An Activatable Polymeric Nanoprobe for Fluorescence and Photoacoustic Imaging of Tumor‐Associated Neutrophils in Cancer Immunotherapy
5个月前
已完结
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms
6个月前
已完结
皖公网安备34019202002308
